UK Urged To Fund Rare Disease Treatments Immediately
Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.
You may also be interested in...
A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.